Medical News

RSS

AUA Foundation introduces It's Time to Talk About OAB campaign

On the heels of the fourth annual World Continence Week, the American Urological Association (AUA) Foundation has launched "It's Time to Talk About OAB," a nationwide education campaign designed to elevate awareness of Overactive Bladder (OAB), a common, yet often untreated condition, as a public health issue.

20 Jun 2012

Six novel genetic associations for early onset male pattern baldness

Using data from its unique online research platform, 23andMe, a leading personal genetics company, has contributed to the finding of six novel genetic associations for early onset male pattern baldness (androgenetic alopecia) in a genome-wide association study now published online in the journal PLoS Genetics.

20 Jun 2012

GenMark intends to commence underwritten public offering of common stock

GenMark Diagnostics, Inc., a provider of automated, multiplex molecular diagnostic testing systems, announced today that it intends to commence an underwritten public offering of 10,000,000 shares of its common stock. All of the shares in the proposed offering are to be sold by GenMark.

20 Jun 2012

Furiex initiates MuDelta Phase III studies in IBS-D

Furiex Pharmaceuticals, Inc. today announced dosing of the first patient in its Phase III randomized, double-blind, placebo-controlled studies evaluating efficacy, safety and tolerability of MuDelta (JNJ-27018966) in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

20 Jun 2012

New approach to decipher roles of genes associated with autism

Fish cannot display symptoms of autism, schizophrenia or other human brain disorders. However, a team of MIT biologists has shown that zebrafish can be a useful tool for studying the genes that contribute to such disorders.

20 Jun 2012

CAE Healthcare, Elsevier to launch new electronic nursing education solution

Elsevier a world-leading provider of scientific, technical and medical information products and services, and CAE Healthcare, a leading provider of medical simulation and health care learning solutions, today announced a new electronic nursing education solution to be made available in July.

20 Jun 2012

Viewpoints: For Fla. small business owner, loss of health law would be 'real blow;' Effort to silence Mich. legislators backfires

Running a small business with four employees, I've got a lot hanging in the balance as the Supreme Court deliberates on the healthcare law. The legal challenge to the law was launched here in Florida with a small business lobby group as a plaintiff in the case. But if you're thinking that means small business people like me want to see the law rolled back, think again. The simple fact is, the healthcare law is saving our business serious money and saving our healthcare benefits.

20 Jun 2012

Covidien introduces knotless suturing device for laparoscopic surgery

Covidien, a leading global provider of healthcare products, today announced the latest additions to its growing bariatric surgery portfolio of products and services designed to improve patient and surgeon experiences with weight loss surgery and other procedures.

19 Jun 2012

Grunenthal to commercialize Horizon Pharma's DUEXIS in Latin America

Horizon Pharma, Inc. a biopharmaceutical company developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases, today announced that it entered into an exclusive agreement with Grunenthal for the commercialization of DUEXIS in Latin America.

19 Jun 2012

Positive results from Zalicus Z944 Phase 1 SAD clinical study for chronic inflammatory pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, announced that it is has successfully completed a Phase 1 single ascending dose (SAD) clinical study with Z944, its novel, oral, T-type calcium channel blocker.

19 Jun 2012

FDA, EMA grant orphan drug designation to bluebird bio's gene therapy product for adrenoleukodystrophy

bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, announced today that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted an orphan drug designation to its investigational gene therapy product for the treatment of adrenoleukodystrophy (ALD).

19 Jun 2012

AstraZeneca, Rigel enter global license agreement for R256 inhaled JAK inhibitor to treat chronic asthma

AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.

19 Jun 2012